AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
6.21
+0.14 (2.31%)
May 28, 2025, 4:00 PM - Market closed
AVITA Medical Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for AVITA Medical stock ranges from a low of $12 to a high of $22. The average analyst price target of $17.25 forecasts a 177.78% increase in the stock price over the next year.
Price Target: $17.25 (+177.78%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 10, 2025.
Analyst Ratings
The average analyst rating for AVITA Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $22 | Strong Buy | Maintains | $22 | +254.27% | Apr 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $22 | Strong Buy | Maintains | $22 | +254.27% | Apr 4, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $22 | Strong Buy | Maintains | $22 | +254.27% | Mar 18, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 → $22 | Strong Buy | Maintains | $25 → $22 | +254.27% | Feb 20, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +302.58% | Feb 14, 2025 |
Financial Forecast
Revenue This Year
102.48M
from 64.25M
Increased by 59.50%
Revenue Next Year
132.09M
from 102.48M
Increased by 28.89%
EPS This Year
-0.68
from -2.39
EPS Next Year
-0.18
from -0.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 110.4M | 147.0M | 312.9M | ||
| Avg | 102.5M | 132.1M | 188.1M | ||
| Low | 90.7M | 121.4M | 142.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.7% | 43.4% | 136.8% | ||
| Avg | 59.5% | 28.9% | 42.4% | ||
| Low | 41.1% | 18.5% | 7.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.18 | -0.04 | 5.46 | ||
| Avg | -0.68 | -0.18 | 1.70 | ||
| Low | -0.99 | -0.30 | -0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.